Chairman's Report
Our corporate mission to apply innovative medicare solutions for the early detection and prevention of diseases including chronic and life threatening diseases such as cancer has an eventual goal of enhancing human health and quality of life of all individuals.
Early screening of life threatening diseases is becoming a critical link to modern medicine today..Our products, used for early screening of asymptomatic patients, provide early awareness of potential problems to patients, and in many situations lead to timely and accurate diagnosis. In our experience, early screening for cancers provide the patients with early medical interventions, therapeutic opportunities and most importantly, their survival probabilities.
Finding better and faster ways to achieve accurate diagnosis can potentially improve patient management,lead to earlier therapeutic intervention and reduce the costs associated with indecision, benefiting both patients and healthcare providers.
At the 58th World Health Assembly in 2005, the Member States of the World Health Organization adopted a resolution on Cancer Prevention and Control. This resolution calls on all Member States to develop national cancer programmes, which include increased prevention measures, early detection and screening,as well as improved treatment and palliative care. The global direction on early screening coincides with our Group’s founding mission and the Group’s C12 products have met the basic criteria of low cost, high throughput and non invasive factors for early cancer screening for developing countries, including China.
Being an early and leading pioneer of innovative medicare solutions in China, the Board is committed to its corporate mission, and we believe that a successful implementation of the goal will enhance human health and quality of life, directly enhance shareholders’ value and secure the future growth of the company.”
Early screening of life threatening diseases is becoming a critical link to modern medicine today..Our products, used for early screening of asymptomatic patients, provide early awareness of potential problems to patients, and in many situations lead to timely and accurate diagnosis. In our experience, early screening for cancers provide the patients with early medical interventions, therapeutic opportunities and most importantly, their survival probabilities.
Finding better and faster ways to achieve accurate diagnosis can potentially improve patient management,lead to earlier therapeutic intervention and reduce the costs associated with indecision, benefiting both patients and healthcare providers.
At the 58th World Health Assembly in 2005, the Member States of the World Health Organization adopted a resolution on Cancer Prevention and Control. This resolution calls on all Member States to develop national cancer programmes, which include increased prevention measures, early detection and screening,as well as improved treatment and palliative care. The global direction on early screening coincides with our Group’s founding mission and the Group’s C12 products have met the basic criteria of low cost, high throughput and non invasive factors for early cancer screening for developing countries, including China.
Being an early and leading pioneer of innovative medicare solutions in China, the Board is committed to its corporate mission, and we believe that a successful implementation of the goal will enhance human health and quality of life, directly enhance shareholders’ value and secure the future growth of the company.”
Mr. Yao Yuan, Chairman of the Board
